TNF Receptor

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody with antitumor activity, useful for studying advanced solid tumors.

Ruplizumab (BG 9588) is a humanized IgG1κ-like monoclonal antibody against CD40L. Ruplizumab is used in the study of neurological and immune system disorders.

Tebentafusp (IMCgp100) is a protein that specifically targets gp100 and consists of a soluble T-cell receptor functionally fused to an anti-CD3 immune effector Tebentafusp has potential anti-tumor activity, induces the production of inflammatory cytokines and cytolytic proteins, and can be used to study unresectable or metastatic uveal melanoma.

Belimumab(LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF).Belimumab is used in the study of fatigue and in the treatment of lupus nephritis and systemic lupus erythematosus.

Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).

Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

Lenercept (Ro 45-2081) is a recombinant fusion protein that combines the soluble TNF-receptor (p55) with the Fc portion of human IgG1 [1].

Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells.

Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I.

Tavolixizumab (also known as MEDI 0562 and Tavolimab) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4), utilized in cancer immunology studies [1].

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

ABBV-154 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized antibody Adalimumab linked to a glucocorticoid receptor modulator. It is employed in the research of rheumatoid arthritis, Crohn's disease, and polymyalgia rheumatica.

ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized TNF antibody adalimumab and a glucocorticoid receptor agonist. It is designed for use in research related to rheumatoid arthritis.